carbapenems has been researched along with Disease Models, Animal in 71 studies
*Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.45) | 18.2507 |
| 2000's | 11 (15.49) | 29.6817 |
| 2010's | 39 (54.93) | 24.3611 |
| 2020's | 15 (21.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, J; Ding, M; Li, Q; Liang, Q; Liang, S; Wang, G; Yan, X; Zhang, B; Zhang, F; Zhou, Y | 1 |
| Enoki, Y; Hayashi, M; Igarashi, Y; Kojima, N; Liu, X; Matsumoto, K; Mizukami, Y; Morita, T; Nakamura, T; Taguchi, K; Takemura, W; Tashiro, S; Yokoyama, Y | 1 |
| Du, X; He, J; Hua, X; Moran, RA; van Schaik, W; Yu, Y; Zeng, X; Zhang, J; Zou, Q | 1 |
| Al-Madboly, LA | 1 |
| Aanensen, DM; Beis, K; Brett, SJ; Clements, A; David, S; Frankel, G; Giani, T; Low, WW; Morecchiato, F; Rossolini, GM; Rouskin, S; Sanchez-Garrido, J; Wong, JLC; Woo, JZ | 1 |
| Kim, M; Kim, Y; Krishnan, M; Lee, H; Yoon, YK | 1 |
| A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
| Bhaskar, A; Chaturvedi, S; Dwivedi, VP; Ghoshal, A; Kumari, A; Mukhopadhyay, S; Pahuja, I; Shaji, A; Verma, A | 1 |
| Ahn, JY; Choi, H; Choi, JY; Choi, YH; Jeong, SJ; Kim, JM; Ku, NS; Lee, SH; Lim, YS; Shin, SJ; Song, YG; Yeom, JS; Yong, D | 1 |
| Ábrahám, H; Horváth, M; Koderivalappil, S; Kovács, T; Rákhely, G; Schneider, G | 1 |
| Dinc, G; Doganay, M; Eren, E; Kontas, O | 1 |
| Barquist, L; Blaskovich, MAT; Boinett, CJ; Butler, MS; Cain, AK; Cooper, MA; Edwards, IA; Elliott, AG; Huang, JX; Lociuro, S; Lundberg, CV; Mobli, M; Neve, S; Porter, KM; Steen, J; Strandh, M; Zuegg, J | 1 |
| Álvarez-Fraga, L; Beceiro, A; Bou, G; Gato, E; Martínez-Guitián, M; Oteo Iglesias, J; Pérez, A; Pérez-Vázquez, M; Poza, M; Ramos Vivas, J; Rodiño-Janeiro, BK; Romero, A; Rumbo-Feal, S; Sola Campoy, PJ; Vallejo, JA; Vázquez-Ucha, JC | 1 |
| Hu, YM; Li, J; Li, YJ; Luo, Y; Peng, JY; Tao, XY; Wang, HC; Yu, T; Zou, MX | 1 |
| Chen, C; Yang, K | 1 |
| Chen, JW; Chia, JS; Chuang, YC; Hsu, CC; Huang, TY; Jung, CJ; Kuo, YM; Liao, YD | 1 |
| Horvath, A; Ostorhazi, E; Otvos, L; Szabo, D | 1 |
| Cai, Y; Wang, J; Wang, R; Yang, D | 1 |
| Band, VI; Burd, EM; Farley, MM; Jacob, JT; Satola, SW; Weiss, DS | 1 |
| Jain, A; Pucci, MJ; Rubio, A | 1 |
| Batista, MV; Costa, SF; Guimaraes, T; Leite, G; Levin, AS; Neves, PR; Perdigão Neto, LV; Ramos, JF; Rocha, V; Rossi, F; Ruedas Martins, RC; Sanabani, SS | 1 |
| Hefzy, EM; Khalil, MAF; Moawad, SS | 1 |
| Growcott, EJ; Nguyen, P; Pulse, ME; Weiss, WJ | 1 |
| Chen, L; Goodman, AL; Jung, HJ; Kreiswirth, BN; Leiner, IM; Ling, L; Littmann, ER; Pamer, EG; Peled, J; Seok, R; Taur, Y; van den Brink, M | 1 |
| Jeon, J; Park, JH; Yong, D | 1 |
| Charernmak, B; Chongsuvivatwong, V; Chusri, S; Doi, Y; Hortiwakul, T; Silpapojakul, K; Singkhamanan, K | 1 |
| Al Zayer, M; Alghoribi, MF; Aljohani, SM; Alrodayyan, M; Balkhy, HH; Desin, TS; Doumith, M; Köster, WL; Muhanna, A | 1 |
| Aprameya, IV; Chakravortty, D; Chandra, N; Datey, A; Kulkarni, O; Nagarajan, D; Nanajkar, N; Ravichandran, S; Roy, N; Sarma, SP; T, S; Thakur, C | 1 |
| Fang, C; Hou, Z; Hu, Y; Li, M; Lu, L; Luo, X; Ma, B; Wang, M; Xue, X; Zhou, Y | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, C | 1 |
| Crandon, JL; Nicolau, DP; Wiskirchen, DE | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 3 |
| Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F; Metan, G | 2 |
| Aschard, H; Cattoir, V; Danilchanka, O; Gaultier, C; Guerin, F; Guillard, T; Han, K; Jiang, D; Leclercq, R; Lory, S; Lu, X; Mekalanos, JJ; Pier, GB; Roux, D; Skurnik, D; Yoder-Himes, DR | 1 |
| Betts, JW; Hornsey, M; Phee, LM; Wareham, DW; Woodford, N | 1 |
| Crandon, JL; MacVane, SH; Nichols, WW; Nicolau, DP | 1 |
| Arora, R; Chawla, R; Goel, R; Narula, A; Sharma, RK; Thakur, P | 1 |
| Jaganath, D; Lamichhane, G; Shah, M | 1 |
| Chen, L; DeLeo, FR; Dorward, DW; Freedman, B; Kobayashi, SD; Kreiswirth, BN; Porter, AR | 1 |
| Cheong, HJ; Kim, WJ; Lee, J; Song, JY; Sung, AK | 1 |
| Chen, CC; Chen, CH; Chiang, SR; Chou, CH; Chuang, YC; Ko, WC; Lee, NY; Tang, HJ | 1 |
| Bethel, CR; Binas, A; Bonomo, RA; Cassone, M; Nolte, O; Ostorhazi, E; Otvos, L; Rozgonyi, F; Szabo, D; Wade, JD | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
| Chryssouli, Z; Galani, I; Giamarellos-Bourboulis, E; Giamarellou, H; Konstantinidou, E; Pefanis, A; Souli, M; Tsaganos, T; Tzepi, I | 1 |
| Cheong, HJ; Choi, WS; Heo, JY; Kim, WJ; Noh, JY; Song, JY | 1 |
| Arthur, M; Gutmann, L; Hugonnet, JE; Mainardi, JL | 1 |
| Chen, CC; Chen, CH; Chiang, SR; Chuang, YC; Ko, WC; Lee, NY; Shieh, JM; Tang, HJ | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Egerman, U; Laeuffer, JM; Stucki, A | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Dimopoulou, D; Galanakis, E; Kofteridis, DP; Maraki, S; Ntaoukakis, M; Samonis, G; Sarchianaki, E; Spathopoulou, T | 1 |
| Caprioli, RM; Chazin, WJ; Hood, MI; Kehl-Fie, TE; Moore, JL; Mortensen, BL; Skaar, EP; Sugitani, N; Zhang, Y | 1 |
| Ariza, J; Ayats, J; Borraz, C; Cabellos, C; Corbella, X; Doménech, A; Gudiol, F; Montero, A; Tubau, F | 1 |
| Endo, M; Gondaira, F; Hatakeyama, K; Iwakura, N; Iwaya, A; Kurihara, M; Kuwano, T; Nakagawa, S; Taneike, I; Yamamoto, T | 1 |
| Abe, T; Fukuoka, T; Hirota, T; Inoue, H; Kakuta, M; Kitayama, A; Koga, T; Kuwahara, S; Masuda, N; Matsushita, Y; Nakagawa, M; Ohya, S; Shibayama, T; Sugihara, C; Takenouchi, T; Utsui, Y; Yoshida, T | 1 |
| Hirai, Y; Kijima, K; Kurazono, M; Nagura, J; Shitara, E; Sugano, T; Takahata, S; Takayama, Y; Tanaka, Y; Yamada, K; Yonezawa, M | 1 |
| Katsube, T; Yamano, Y; Yano, Y | 1 |
| Araki, N; Izumikawa, K; Kakeya, H; Kamihira, S; Kihara, R; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Tsukamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Banevicius, MA; Kim, A; Nicolau, DP | 1 |
| Brughera, M; Dayan, AD; Iatropoulos, MJ; Mazue, G; Newman, AJ; Scampini, G | 1 |
| Fukuoka, T; Harasaki, T; Iwata, M; Kamai, Y; Kawada, H; Kitayama, A; Koga, T; Kubota, M; Kuwahara, S; Ohya, S; Yasuda, H | 1 |
| Ishii, Y; Miyazaki, S; Ohno, A; Tsuji, M; Yamaguchi, K | 1 |
| Horii, T; Ichiyama, S; Kobayashi, M; Nadai, M; Ohta, M | 1 |
| Matsuda, K; Matsumoto, S; Matsumoto, Y; Sasaki, H; Takasugi, H; Yoshida, Y | 1 |
| Hayasaki, Y; Hua, YX; Izumi, K; Mikamo, H; Sato, Y; Tamaya, T | 1 |
| Tateda, K; Yamaguchi, K | 1 |
| Lahnborg, G; Nord, CE | 1 |
3 review(s) available for carbapenems and Disease Models, Animal
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Carbapenems against Mycobacterium tuberculosis: a review of the evidence.
Topics: Animals; Antitubercular Agents; beta-Lactamases; Carbapenems; Cell Wall; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Incidence; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Prevalence; Randomized Controlled Trials as Topic | 2016 |
[Penicillin-resistant Streptococcus pneumoniae infections: current trends in epidemiology and antibiotic chemotherapy].
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Humans; Japan; Mice; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae; Vancomycin | 2000 |
2 trial(s) available for carbapenems and Disease Models, Animal
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing.
Topics: Animals; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Female; High-Throughput Nucleotide Sequencing; Humans; Hydrogen-Ion Concentration; Macrophages; Male; Mice; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
67 other study(ies) available for carbapenems and Disease Models, Animal
| Article | Year |
|---|---|
Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Klebsiella pneumoniae; Meropenem; Mice; Microbial Sensitivity Tests; Treatment Failure | 2021 |
Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefmetazole; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Humans; Mice; Microbial Sensitivity Tests; Neutropenia | 2021 |
Phenotypic and Genotypic Characterization of a Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae ST17-KL38 Clinical Isolate Harboring the Carbapenemase IMP-4.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Mice; Plasmids; Protein Synthesis Inhibitors; Serogroup | 2022 |
A Novel Triple Combination To Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Ascorbic Acid; Biological Factors; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Imipenem; Inflammation; Mice; Microbial Sensitivity Tests; Pneumonia; Transferrins | 2022 |
Recurrent emergence of
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Carbapenems; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Mutation; Phylogeny; Pneumonia, Bacterial; Porins; RNA, Messenger | 2022 |
Rhamnetin, a Natural Flavonoid, Ameliorates Organ Damage in a Mouse Model of Carbapenem-Resistant
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Carbapenems; Disease Models, Animal; Escherichia coli; Flavonoids; Mice; Microbial Sensitivity Tests; Sepsis | 2022 |
Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; CD8-Positive T-Lymphocytes; COVID-19; Disease Models, Animal; Immunity; Immunologic Factors; Mice; Mycobacterium tuberculosis; Tuberculosis | 2023 |
In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Fosfomycin; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Minocycline; Pneumonia; Tigecycline | 2019 |
Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; Biological Therapy; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disease Models, Animal; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Phylogeny; Siphoviridae | 2020 |
The efficacy of mesenchymal stem cell therapy in experimental sepsis induced by carbapenem-resistant K. pneumoniae in neutropenic mice model.
Topics: Animals; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Klebsiella pneumoniae; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Neutropenia; Sepsis | 2020 |
An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Carbapenems; Cell Membrane Permeability; Colistin; Disease Models, Animal; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Helminth Proteins; Humans; Male; Mice; Microbial Sensitivity Tests; Peritonitis; Pneumonia; Urinary Tract Infections | 2020 |
Kpi, a chaperone-usher pili system associated with the worldwide-disseminated high-risk clone
Topics: A549 Cells; Animals; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Carbapenems; Cell Line; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Epithelial Cells; Europe; Female; Fimbriae, Bacterial; Gene Deletion; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred BALB C; Molecular Chaperones; Multilocus Sequence Typing; Operon; Phylogeny | 2020 |
Characterization of carbapenem-resistant hypervirulent Acinetobacter baumannii strains isolated from hospitalized patients in the mid-south region of China.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Animals; Anti-Bacterial Agents; Biofilms; Carbapenems; Child; China; Disease Models, Animal; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Middle Aged; Moths; Phylogeny; Virulence; Young Adult | 2020 |
Ruthenium complexes as prospective inhibitors of metallo-β-lactamases to reverse carbapenem resistance.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Carbapenems; Coordination Complexes; Disease Models, Animal; Drug Development; Drug Resistance, Microbial; Escherichia coli; Infections; Meropenem; Mice; Microbial Sensitivity Tests; Prospective Studies; Protein Binding; Protein Conformation; Ruthenium; Structure-Activity Relationship; Zinc | 2020 |
Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Biofilms; Carbapenems; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Design; Drug Resistance, Multiple, Bacterial; Hemolysis; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peptides; Pneumonia; Pore Forming Cytotoxic Proteins; Stem Cells | 2021 |
Transdermally administered proline-arginine-rich host defense peptides show systemic efficacy in a lethal mouse bacteremia model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Cutaneous; Amino Acid Sequence; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Arginine; Bacteremia; Bacterial Load; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Ear; Humans; Mice; Proline; Skin; Survival Analysis | 2017 |
Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefoperazone; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Luminescent Measurements; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2018 |
Carbapenem-Resistant
Topics: Animals; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Enterobacteriaceae; Klebsiella Infections; Klebsiella pneumoniae; Mice; Polymyxins | 2018 |
Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.
Topics: Administration, Intravenous; Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Biological Availability; Carbapenems; Disease Models, Animal; Gastrointestinal Microbiome; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome; Urinary Tract Infections | 2018 |
Carbapenem-resistant Pseudomonas aeruginosa carrying bla
Topics: Animals; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Carbapenems; Disease Models, Animal; DNA, Bacterial; Larva; Microbial Sensitivity Tests; Moths; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Virulence | 2019 |
In vivo activity of co-trimoxazole combined with colistin against Acinetobacter baumannii producing OXA-23 in a Galleria mellonella model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Lepidoptera; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination | 2019 |
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disease Models, Animal; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Monobactams; Pyelonephritis | 2019 |
Genome-Wide Screening for Enteric Colonization Factors in Carbapenem-Resistant ST258 Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disease Models, Animal; DNA Transposable Elements; Genetic Testing; Genome, Bacterial; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mutagenesis, Insertional; Virulence Factors | 2019 |
Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acute Disease; Animals; Anti-Bacterial Agents; Bacteriophages; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Female; Larva; Mice; Mice, Inbred C57BL; Moths; Phage Therapy; Pneumonia, Bacterial; Republic of Korea | 2019 |
Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Animals; Anti-Bacterial Agents; Bacteremia; Carbapenems; Community-Acquired Infections; Disease Models, Animal; Female; Hospitals; Humans; Kaplan-Meier Estimate; Larva; Male; Microbial Sensitivity Tests; Middle Aged; Mortality; Retrospective Studies; Risk Factors; Virulence | 2019 |
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Genotype; Humans; Membrane Proteins; Salmonella enteritidis; Salmonella typhimurium; Saudi Arabia; Serogroup; Serotyping; Type III Secretion Systems; Typhoid Fever; Virulence; Virulence Factors | 2019 |
Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Antimicrobial Cationic Peptides; Carbapenems; Cell Membrane; Disease Models, Animal; Drug Design; Drug Resistance, Multiple, Bacterial; HeLa Cells; Humans; Kinetics; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritoneum; Protein Structure, Secondary; Tigecycline; Time Factors | 2019 |
The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Catalytic Domain; Cell Wall; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Zinc | 2019 |
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Ertapenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Treatment Outcome | 2013 |
Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Disease Models, Animal; Drug Therapy, Combination; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Neutropenia; Treatment Outcome | 2013 |
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Time Factors | 2013 |
Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Klebsiella pneumoniae; Methylprednisolone; Methylprednisolone Acetate; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Sepsis; Structure-Activity Relationship; Tigecycline | 2014 |
In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Sepsis; Sulbactam; Tigecycline; Time Factors | 2013 |
In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Moths; Tigecycline | 2014 |
Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Disease Models, Animal; Drug Combinations; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests | 2014 |
Assessment of aquo-ethanolic extract of Camellia sinensis against Carbapenem Resistant Escherichia coli: In Vivo Trials in a Murine Model.
Topics: Animals; Camellia sinensis; Carbapenems; Chromatography, Liquid; Disease Models, Animal; Drug Resistance, Bacterial; Escherichia coli; Ethanol; Humans; Kidney; Male; Mass Spectrometry; Maximum Tolerated Dose; Mice; Peritonitis; Plant Extracts; Rats, Sprague-Dawley; Reference Standards; Water | 2016 |
Survival of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 in Human Blood.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Carbapenems; Disease Models, Animal; Humans; Klebsiella pneumoniae; Mice; Mice, Inbred BALB C; Multilocus Sequence Typing; Virulence | 2017 |
Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Immunosuppression Therapy; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Pneumonia, Bacterial; Rifampin; Treatment Outcome | 2009 |
Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Female; Mice; Mice, Inbred BALB C; Pneumonia, Bacterial; Time Factors; Trachea | 2009 |
Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Female; Mice; Peptides | 2011 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Humans; Male; Rabbits; Rodent Diseases; Treatment Outcome | 2011 |
Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Animals; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Disease Models, Animal; Female; Genes, Bacterial; Humans; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Republic of Korea; Rifampin; Risk Factors | 2011 |
Fighting resistant tuberculosis with old compounds: the carbapenem paradigm.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Mice; Mycobacterium tuberculosis; Treatment Outcome | 2011 |
Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acute Disease; Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Cytokines; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia, Bacterial; Stem Cells; Thienamycins | 2012 |
Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Cefepime; Cephalosporins; Disease Models, Animal; Doripenem; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Meningitis, Bacterial; Rabbits; Treatment Outcome | 2012 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
Effects of carbapenems and their combination with amikacin on murine gut colonisation by Candida albicans.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Candida albicans; Candidiasis; Carbapenems; Disease Models, Animal; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Male; Mice | 2013 |
Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Biological Transport, Active; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Humans; Leukocyte L1 Antigen Complex; Lung; Manganese; Mice; Mice, Knockout; Neutrophil Infiltration; Neutrophils; Pneumonia, Bacterial; Zinc | 2012 |
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rifampin; Tobramycin | 2004 |
Rapid and quantitative detection of blood Serratia marcescens by a real-time PCR assay: its clinical application and evaluation in a mouse infection model.
Topics: Animals; Carbapenems; Disease Models, Animal; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Male; Mice; Mice, Inbred C57BL; Polymerase Chain Reaction; Sensitivity and Specificity; Sepsis; Serratia Infections; Serratia marcescens | 2005 |
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Mice; Microbial Sensitivity Tests | 2005 |
Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Endocarditis, Bacterial; Female; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2005 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Blood-Borne Pathogens; Bronchopneumonia; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Humans; Lung; Male; Methicillin Resistance; Mice; Pneumonia, Staphylococcal; Specific Pathogen-Free Organisms; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vancomycin Resistance | 2008 |
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hydrogen-Ion Concentration; Hyperplasia; Kidney; Lactams; Male; Precancerous Conditions; Rats; Time Factors; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urine | 1994 |
Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.
Topics: Animals; Carbapenems; Disease Models, Animal; Drug Evaluation, Preclinical; Lung; Male; Mice; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Prodrugs; Streptococcus pneumoniae; Treatment Outcome | 1998 |
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Doripenem; Enterobacteriaceae; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Moraxella; Penicillin Resistance; Pneumococcal Infections | 1998 |
Carbapenem-induced endotoxin release in gram-negative bacterial sepsis rat models.
Topics: Animals; Bacterial Toxins; Carbapenems; Disease Models, Animal; Endotoxins; Enterobacteriaceae; Gram-Negative Bacteria; Pseudomonas aeruginosa; Rats; Rats, Wistar; Sepsis | 1998 |
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clarithromycin; Disease Models, Animal; Helicobacter pylori; Lactams; Mice; Molecular Structure | 1999 |
In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Microbial Sensitivity Tests; Rats; Uterine Diseases | 2000 |
Efficacy of L-627, a new carbapenem, in the treatment of experimentally induced intra-abdominal infections in rats.
Topics: Abdomen; Animals; Bacterial Infections; Carbapenems; Disease Models, Animal; Gentamicins; Intestines; Male; Metronidazole; Rats; Rats, Sprague-Dawley; Thienamycins | 1992 |